XML 22 R6.htm IDEA: XBRL DOCUMENT v3.24.3
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF STOCKHOLDERS' DEFICIT - USD ($)
$ in Thousands
Total
Series A-1 Convertible Preferred Stock
Series B Convertible Preferred Stock
Redeemable Preferred Stock
Common Stock
Common Stock
Series A-1 Convertible Preferred Stock
Common Stock
Series B Convertible Preferred Stock
Additional Paid-in Capital
Additional Paid-in Capital
Series A-1 Convertible Preferred Stock
Additional Paid-in Capital
Series B Convertible Preferred Stock
Accumulated Other Comprehensive Loss
Accumulated Deficit
Beginning Balance at Dec. 31, 2021 $ 4,837       $ 3     $ 99,282       $ (94,448)
Beginning Balance (in shares) at Dec. 31, 2021         26,807,365              
Exercise of stock options 128             128        
Exercise of stock options, (in shares)         128,567              
Stock-based compensation expense 437             437        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants   $ 24 $ 4           $ 24 $ 4    
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)           5,611 1,028          
Issuance of common stock for the exercise of Public Warrants (in shares)         137,285              
Net loss (37,744)                     (37,744)
Ending Balance at Dec. 31, 2022 (32,314)       $ 3     99,875       (132,192)
Ending Balance (in shares) at Dec. 31, 2022         27,079,856              
Exercise of stock options 20             20        
Exercise of stock options, (in shares)         15,376              
Stock-based compensation expense 409             409        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants 29             29        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)         3,554              
Net loss (17,801)                     (17,801)
Ending Balance at Mar. 31, 2023 (49,657)       $ 3     100,333       (149,993)
Ending Balance (in shares) at Mar. 31, 2023         27,098,786              
Beginning Balance at Dec. 31, 2022 (32,314)       $ 3     99,875       (132,192)
Beginning Balance (in shares) at Dec. 31, 2022         27,079,856              
Net loss (61,427)                      
Ending Balance at Sep. 30, 2023 (52,756)       $ 5     140,858       (193,619)
Ending Balance (in shares) at Sep. 30, 2023         47,460,941              
Beginning Balance at Dec. 31, 2022 (32,314)       $ 3     99,875       (132,192)
Beginning Balance (in shares) at Dec. 31, 2022         27,079,856              
Exercise of stock options 145             145        
Exercise of stock options, (in shares)         298,562              
Stock-based compensation expense 8,357             8,357        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants   $ 6 $ 89           $ 6 $ 89    
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)           492 8,530          
Reverse recapitalization, net of transaction costs 58,573       $ 1     58,572        
Reverse recapitalization, net of transaction costs (in shares)         13,735,872              
Recognition of warrant liabilities in connection with the Merger (13,762)             (13,762)        
Issuance of common stock in connection with vesting of RSU awards (in shares)         918,412              
Issuance of common stock for the conversion of convertible notes 25,570       $ 1     25,569        
Issuance of common stock for the conversion of convertible notes (in shares)         3,301,222              
Recognition of earn-out liabilities (Note 3) (53,040)             (53,040)        
Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification 929             929        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares 16,098             16,098        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)         2,287,696              
Issuance of common stock for the exercise of Public Warrants 46             46        
Issuance of common stock for the exercise of Public Warrants (in shares)         21,943              
Issuance of common stock for commitment shares for equity line financing 123             123        
Issuance of common stock for commitment shares for equity line financing (in shares)         35,511              
Other comprehensive income (loss) (700)                   $ (700)  
Net loss (80,607)                     (80,607)
Ending Balance at Dec. 31, 2023 $ (70,487)       $ 5     143,007     (700) (212,799)
Ending Balance (in shares) at Dec. 31, 2023         47,688,096              
Temporary Equity, Balance (in Shares) at Dec. 31, 2023 0                      
Beginning Balance at Mar. 31, 2023 $ (49,657)       $ 3     100,333       (149,993)
Beginning Balance (in shares) at Mar. 31, 2023         27,098,786              
Exercise of stock options 28             28        
Exercise of stock options, (in shares)         27,626              
Stock-based compensation expense 401             401        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants 6             6        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)         492              
Net loss (21,996)                     (21,996)
Ending Balance at Jun. 30, 2023 (71,218)       $ 3     100,768       (171,989)
Ending Balance (in shares) at Jun. 30, 2023         27,126,904              
Exercise of stock options 83             83        
Exercise of stock options, (in shares)         77,214              
Stock-based compensation expense 5,539             5,539        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants 60             60        
Issuance of Legacy Allurion convertible preferred stock for the exercise of warrants (in shares)         4,976              
Reverse recapitalization, net of transaction costs 58,573       $ 1     58,572        
Reverse recapitalization, net of transaction costs (in shares)         13,735,872              
Recognition of warrant liabilities in connection with the Merger (13,762)             (13,762)        
Issuance of common stock in connection with vesting of RSU awards (in shares)         906,551              
Issuance of common stock for the conversion of convertible notes 25,570       $ 1     25,569        
Issuance of common stock for the conversion of convertible notes (in shares)         3,301,222              
Recognition of earn-out liabilities (Note 3) (53,040)             (53,040)        
Reclassification of Legacy Allurion liabilitiy classified warrants to equity classification 929             929        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares 16,098             16,098        
Derecognition of liabilities associated with the Backstop Shares, Hunter shares, and the additional RTW and Fortress shares and issuance of related shares (in shares)         2,287,696              
Issuance of common stock for the exercise of Public Warrants 42             42        
Issuance of common stock for the exercise of Public Warrants (in shares)         20,506              
Net loss (21,630)                     (21,630)
Ending Balance at Sep. 30, 2023 (52,756)       $ 5     140,858       (193,619)
Ending Balance (in shares) at Sep. 30, 2023         47,460,941              
Ending Balance, temporary stocks 0                      
Beginning Balance at Dec. 31, 2023 (70,487)       $ 5     143,007     (700) (212,799)
Beginning Balance (in shares) at Dec. 31, 2023         47,688,096              
Exercise of stock options 9             9        
Exercise of stock options, (in shares)         4,646              
Stock-based compensation expense 552             552        
Stock issued during period value 378             378        
Stock isssued during the period (in shares)         143,234              
Issuance of common stock in connection with vesting of RSU awards (in shares)         62,619              
Issuance of common stock for the exercise of Public Warrants (in shares)         142              
Other comprehensive income (loss) (2,200)                   (2,200)  
Net loss 5,586                     5,586
Ending Balance at Mar. 31, 2024 (66,162)       $ 5     143,946     (2,900) (207,213)
Ending Balance (in shares) at Mar. 31, 2024         47,898,737              
Beginning Balance at Dec. 31, 2023 (70,487)       $ 5     143,007     (700) (212,799)
Beginning Balance (in shares) at Dec. 31, 2023         47,688,096              
Net loss (5,580)                      
Ending Balance at Sep. 30, 2024 $ (64,790)       $ 7     150,692     2,890 (218,379)
Ending Balance (in shares) at Sep. 30, 2024         64,369,381              
Temporary Equity, Balance (in Shares) at Sep. 30, 2024 2,260,159     2,260,159                
Beginning Balance at Mar. 31, 2024 $ (66,162)       $ 5     143,946     (2,900) (207,213)
Beginning Balance (in shares) at Mar. 31, 2024         47,898,737              
Exercise of stock options 16             16        
Exercise of stock options, (in shares)         11,491              
Stock-based compensation expense 805             805        
Issuance of common stock in connection with vesting of RSU awards (in shares)         62,619              
Issuance of common stock for the exercise of Public Warrants 1             1        
Issuance of common stock for the exercise of Public Warrants (in shares)         142              
Other comprehensive income (loss) (3,080)                   (3,080)  
Net loss (2,162)                     (2,162)
Ending Balance at Jun. 30, 2024 (70,582)       $ 5     144,768     (5,980) (209,375)
Ending Balance (in shares) at Jun. 30, 2024         47,972,989              
Stock-based compensation expense 860             860        
Stock issued during period value 5,066       $ 2     5,064        
Stock isssued during the period (in shares)         16,333,773              
Issuance of common stock in connection with vesting of RSU awards (in shares)         62,619              
Other comprehensive income (loss) 8,870                   8,870  
Net loss (9,004)                     (9,004)
Ending Balance at Sep. 30, 2024 $ (64,790)       $ 7     $ 150,692     $ 2,890 $ (218,379)
Ending Balance (in shares) at Sep. 30, 2024         64,369,381              
Temporary Equity, Balance (in Shares) at Sep. 30, 2024 2,260,159     2,260,159                
Issuance of preferred stock in connection with Private Placement, net of issuance costs (in shares)       2,260,159                
Issuance of preferred stock in connection with Private Placement, net of issuance costs       $ 979                
Ending Balance, temporary stocks $ 979     $ 979